Journal Name: Journal of Thoracic Oncology
Journal Type: Q1
ISSN: 15560864, 15561380
Country: United States
Subject Area and Category: Medicine Medicine (miscellaneous) Oncology Pulmonary and Respiratory Medicine
Publisher: Elsevier Inc.
Research Ranking: 60
Publication Type: Journals
H-Index: 190
Coverage: 2006-2025
Editors-in-Chief: Alex Adjei
Research Impact Score: 26.7
Impact Factor: 21
SCIMAGO SJR: 7.948
APC Cost: $4,100
Submission Link: https://www.journals.elsevier.com/journal-of-thoracic-oncology
Contact Email: mary.todd@iaslc.org
Address: 1600 John F. Kennedy Boulevard, Suite 1800. Philadelphia, PA 19103-2899. USA.
Overview
The Journal of Thoracic Oncology (JTO) stands as a premier peer-reviewed medical journal dedicated to the rapidly evolving field of thoracic oncology. Published by the International Association for the Study of Lung Cancer (IASLC), the journal serves as a global platform for the dissemination of high-impact research in lung cancer, mesothelioma, and other thoracic malignancies. It is a critical resource for clinicians, researchers, and healthcare professionals seeking the latest scientific insights and clinical advancements in thoracic oncology.
Scope and Impact of the Journal of Thoracic Oncology
The Journal of Thoracic Oncology covers a broad spectrum of topics, including basic science, translational research, clinical trials, epidemiology, immunotherapy, surgical techniques, radiation oncology, and palliative care. By providing in-depth studies and reviews, JTO significantly contributes to the understanding and treatment of lung cancer and other thoracic tumors. The journal has a high impact factor, reflecting its importance in the academic and clinical oncology communities.
With a strong emphasis on interdisciplinary collaboration, the journal encourages submissions from oncologists, thoracic surgeons, pathologists, radiologists, and specialists involved in thoracic diseases. This collaborative approach fosters innovation and accelerates the development of effective diagnostics and therapies.
Key Features and Contributions
JTO publishes a variety of content types, including original research articles, review papers, case reports, clinical trial results, and expert opinion pieces. One of its standout features is the inclusion of cutting-edge research on immunotherapies and targeted treatments that are revolutionizing lung cancer care.
Additionally, the journal is known for its special issues and editorials that explore emerging trends and challenges in thoracic oncology. Recent publications have focused on precision medicine, biomarker-driven therapies, and disparities in global lung cancer care. These comprehensive analyses make JTO a go-to reference for both ongoing research and clinical decision-making.
Accessibility and Global Reach
The Journal of Thoracic Oncology is accessible both in print and online, ensuring that its content reaches a worldwide audience. Many articles are open access, making crucial findings available to clinicians and researchers regardless of institutional access. The journal’s website offers user-friendly navigation, search functions, and access to supplementary data, making it easier for readers to find relevant studies and insights.
Its global reach is further supported by contributions from authors around the world, which enrich the journal with diverse perspectives and regional insights into thoracic cancer care.
About
The Journal of Thoracic Oncology (JTO) is a prestigious peer-reviewed medical journal dedicated to the field of thoracic oncology. As one of the leading publications in oncology, it plays a vital role in disseminating cutting-edge research, clinical advancements, and critical insights related to the diagnosis, treatment, and management of thoracic cancers, particularly lung cancer.
Scope and Focus of the Journal
The Journal of Thoracic Oncology publishes original research articles, reviews, clinical studies, and editorials focused on thoracic cancers, which include lung cancer, mesothelioma, and other malignancies affecting the chest. The journal's scope covers a wide range of topics, including molecular biology, immunotherapy, targeted therapies, diagnostic methods, and epidemiology. As thoracic oncology continues to evolve, JTO serves as a central hub for the latest breakthroughs and developments in the field.
Impact on the Medical Community
Lung cancer is one of the most common and deadly cancers worldwide, contributing to significant global morbidity and mortality. The Journal of Thoracic Oncology plays an essential role in raising awareness, fostering collaboration among healthcare professionals, and advancing the treatment landscape for thoracic cancer patients. The journal highlights studies on precision medicine, including the identification of biomarkers that predict response to therapies, and the development of novel drugs and therapeutic strategies.
As the treatment paradigm for lung cancer shifts toward personalized approaches, JTO helps physicians stay updated on the latest evidence-based practices and clinical trials. The journal provides clinicians with the necessary tools to make informed decisions, ultimately improving patient outcomes and quality of life.
Editorial Excellence and Collaboration
The Journal of Thoracic Oncology has a distinguished editorial board composed of leading experts in thoracic oncology from around the globe. This expert team ensures that the journal maintains high standards of scientific rigor and clinical relevance. The editorial process focuses on publishing studies that are methodologically sound and contribute meaningfully to the body of knowledge in thoracic oncology.
Moreover, JTO encourages collaboration between academic researchers, clinicians, and industry professionals, facilitating a comprehensive understanding of thoracic cancers and fostering interdisciplinary research. The journal also publishes content related to the socioeconomic and psychological aspects of lung cancer, addressing the multifaceted nature of the disease.
Key Topics Covered in the Journal
Some of the key topics explored in the Journal of Thoracic Oncology include:
-
Lung Cancer Epidemiology: Understanding trends, risk factors, and global statistics.
-
Molecular and Genetic Research: Identifying genetic mutations and molecular mechanisms involved in thoracic cancers.
-
Immunotherapy and Targeted Therapies: Investigating the role of immune checkpoint inhibitors and targeted drugs in treatment.
-
Early Detection and Diagnosis: Advancing techniques such as liquid biopsy and imaging methods to diagnose lung cancer at an earlier stage.
-
Clinical Trials: Reporting the latest results from clinical trials exploring new therapies and treatment regimens.
-
Palliative Care and Quality of Life: Addressing the challenges faced by patients undergoing treatment, including symptom management and psychosocial support.
Why Subscribe to the Journal of Thoracic Oncology?
For researchers, clinicians, and healthcare professionals involved in thoracic oncology, subscribing to the Journal of Thoracic Oncology is invaluable. The journal provides timely access to the latest research and clinical innovations, helping practitioners stay ahead of the curve in the evolving landscape of thoracic cancer treatment. Furthermore, JTO's open-access platform ensures that vital research is accessible to a global audience, improving healthcare outcomes worldwide.
Scope
The Journal of Thoracic Oncology (JTO) serves as a critical publication platform for the global oncology community, specifically focused on thoracic cancer research, treatment, and clinical advancements. As the official journal of the International Association for the Study of Lung Cancer (IASLC), JTO has become a premier resource for oncologists, researchers, and healthcare professionals involved in the diagnosis and management of lung cancer and other thoracic malignancies. With an emphasis on translational research and innovative therapeutic strategies, JTO provides a comprehensive and up-to-date overview of the field’s most significant breakthroughs.
1. Focus on Lung Cancer Research and Treatment
Lung cancer remains one of the most prevalent and deadly cancers worldwide. JTO is dedicated to the exploration of novel therapies, early detection methods, and understanding the complex biology of lung cancer. The journal publishes high-impact articles related to non-small cell lung cancer (NSCLC), small-cell lung cancer (SCLC), and other thoracic cancers. Through in-depth studies, clinical trials, and evidence-based approaches, JTO aims to contribute valuable insights to improve patient outcomes and survival rates.
2. Cutting-Edge Clinical Research
The Journal of Thoracic Oncology emphasizes the importance of clinical research in advancing the treatment of thoracic cancers. It features articles on the latest clinical trials, pharmacological developments, immunotherapy innovations, and precision medicine in thoracic oncology. By prioritizing evidence from randomized controlled trials and large-scale studies, JTO ensures that the content it publishes adheres to the highest standards of scientific rigor, offering oncologists and healthcare providers vital information to guide treatment decisions.
3. Translational Research and Molecular Oncology
One of the journal's defining features is its focus on the molecular and genetic aspects of thoracic cancers. JTO explores the genetic mutations, molecular markers, and signaling pathways that drive lung cancer progression. Research on liquid biopsies, targeted therapies, and personalized medicine is integral to the journal's content. By focusing on translational research, JTO bridges the gap between laboratory discoveries and clinical applications, helping to translate cutting-edge science into practical solutions for patient care.
4. Multidisciplinary Approach to Thoracic Oncology
Thoracic cancer treatment requires a multidisciplinary approach involving medical oncologists, surgeons, radiologists, pathologists, and pulmonologists. JTO promotes collaboration across these disciplines, fostering a comprehensive understanding of lung cancer management. By featuring research on surgical techniques, radiotherapy advancements, and multimodal therapies, JTO highlights the collaborative nature of thoracic oncology and the need for integrated care in improving patient outcomes.
5. Global Perspective and Impact
The Journal of Thoracic Oncology is recognized internationally as a leading resource in thoracic cancer research. It provides a platform for researchers, clinicians, and healthcare professionals worldwide to share findings and discuss emerging trends in thoracic oncology. JTO’s global reach ensures that the latest advancements in lung cancer research are accessible to a diverse audience, encouraging the exchange of ideas and fostering international collaboration in the fight against lung cancer.
6. Educational Content and Resources
Beyond original research articles, JTO also includes educational content such as reviews, editorials, and opinion pieces from experts in the field. These resources help professionals stay updated on evolving best practices, treatment protocols, and emerging technologies in thoracic oncology. Additionally, the journal provides insights into the psychosocial aspects of cancer care, ensuring that all facets of patient well-being are addressed in clinical practice.